Navigation Links
Raptor Pharmaceuticals Doses First Patient in Phase 2b Clinical Trial of DR Cysteamine for Cystinosis
Date:6/1/2009

NOVATO, Calif., June 1 /PRNewswire-FirstCall/ -- Raptor Pharmaceuticals Corp. ("Raptor" or the "Company") (OTC Bulletin Board: RPTP), today announced that it has dosed the first patient in its Phase 2b clinical trial, conducted in collaboration with the University of California, San Diego ("UCSD"), to evaluate Raptor's proprietary delayed-release cysteamine bitartrate ("DR Cysteamine") capsules in nephropathic cystinosis ("cystinosis"), a rare genetic lysosomal storage disease. Under Raptor's open Investigational New Drug application ("IND"), UCSD is performing the Raptor-sponsored trial at its General Clinical Research Center.

(Logo: http://www.newscom.com/cgi-bin/prnh/20071022/NYM074LOGO )

The Phase 2b clinical trial will enroll up to six cystinosis patients with a history of good compliance using the currently available immediate-release form of cysteamine bitartrate, the only drug cleared for marketing by the U.S. Food and Drug Administration ("FDA") and European Medicines Agency ("EMEA") to treat cystinosis. The clinical trial will evaluate safety, tolerability, pharmacokinetics and pharmacodynamics of a single dose of DR Cysteamine in patients. Data from the study are expected in the third quarter of 2009. Raptor plans to follow the Phase 2b clinical study with a pivotal, Phase 3 clinical study in cystinosis patients anticipated to commence in the fourth quarter of 2009.

DR Cysteamine is Raptor's proprietary enteric-coated micro-bead formulation of cysteamine bitartrate contained in a gelatin capsule and designed for increased absorption, less frequent dosing and improved tolerability relative to the current standard of care. Published studies have shown that fewer than 25% of patients taking immediate-release cystea
'/>"/>

SOURCE Raptor Pharmaceuticals Corp.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Vista Partners Updates Coverage on Raptor Pharmaceuticals Corp. (OTC Bulletin Board: RPTP)
2. Raptor Pharmaceuticals Expands Board of Directors and Scientific Advisory Board
3. Raptor Pharmaceuticals Closes $10 Million Private Placement
4. Raptor Pharmaceuticals Corp. Announces Presentation at 5th International Cystinosis Conference 2008
5. Raptor Pharmaceuticals Corp. To Present at BIO 2008 International Convention
6. Raptor Pharmaceuticals Corp. Receives FDA Orphan Drug Designation for Cysteamine in Huntingtons Disease
7. Raptor Pharmaceuticals Corp. Enters Agreements to Advance Clinical Pipeline
8. Raptor Pharmaceuticals Acquires Orphan Clinical Program
9. Peregrine Pharmaceuticals Presents Promising Data From Its Phase II Bavituximab Breast Cancer Trial at 2009 ASCO Annual Meeting
10. Valeant Pharmaceuticals Reports Encouraging Final Results With Taribavirin Phase IIb Study
11. OncoGenex Pharmaceuticals Announces OGX-011 Treatment Provides Survival Benefit in Randomized Phase 2 Trial in Advanced Metastatic Prostate Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... device," Nobel laureate Herbert Kroemer famously observed, referring ... the junctures where layers of different materials meet. ... between layers of metal oxides are becoming increasingly ... spintronics, high-temperature superconductors, ferroelectrics and multiferroics. Realizing the ...
(Date:1/15/2014)... Jan. 15, 2014   Niagara Thermal Products is ... Buffalo BioBlower Technologies LLC ("B3") as the critical thermal ... award from the Army Corps of Engineers.  B3 has ... all biological contaminants and destroys VOCs and other chemical ...
(Date:1/15/2014)... SAN JOSE, California , January 15, 2014 ... for cancer, today announced the appointment of Thomas C Reynolds ... over 20 years, development experience gained in the biotechnology industry, ... "I am delighted to welcome Tom at this transformative ...
(Date:1/15/2014)... A study has been launched to test whether ... could help to tackle the problem of obesity.  This unique ... surgery based in Stowmarket) and academics at University Campus Suffolk ... technology, which is inspired by equipment used to collect data ...
Breaking Biology Technology:A deeper look at interfaces 2Niagara Thermal Products LLC Selected as Critical Supplier for Buffalo BioBlower Air Purification Systems 2Oxford BioTherapeutics Appoints Thomas C Reynolds MD, PhD to its Board of Directors 2Oxford BioTherapeutics Appoints Thomas C Reynolds MD, PhD to its Board of Directors 3Formula 1 Technology Tackles Obesity in Unique Healthcare Partnership 2Formula 1 Technology Tackles Obesity in Unique Healthcare Partnership 3Formula 1 Technology Tackles Obesity in Unique Healthcare Partnership 4
... 19, 2011 OptiScan Biomedical Corporation, a developer ... in intensive care units (ICU), today announced that ... has received CE Mark certification for use in ... the OptiScanner has met all relevant European Union ...
... The ALS Therapy Development Institute (ALS TDI) and ... their current research collaboration agreement to test additional ... stop the progression of Amyotrophic Lateral Sclerosis (ALS, ... collaboration is based on encouraging results from early-stage ...
... LA JOLLA, CA September 15, 2011 Researchers at ... which certain viruses such as influenza trigger a type of ... This severe immune reactioncalled a "cytokine storm"floods the tiny ... blocking off airways and damaging body tissues and organs. Cytokine ...
Cached Biology Technology:OptiScan Biomedical Receives CE Mark for OptiScanner Automatic Bedside Glucose Monitoring System 2OptiScan Biomedical Receives CE Mark for OptiScanner Automatic Bedside Glucose Monitoring System 3OptiScan Biomedical Receives CE Mark for OptiScanner Automatic Bedside Glucose Monitoring System 4ALS Therapy Development Institute and Aestus Therapeutics, Inc., Expand Collaboration on Development of Novel ALS Therapies 2ALS Therapy Development Institute and Aestus Therapeutics, Inc., Expand Collaboration on Development of Novel ALS Therapies 3Scripps Research team discovers treatable mechanism responsible for often deadly response to flu 2Scripps Research team discovers treatable mechanism responsible for often deadly response to flu 3
(Date:7/9/2014)... be able to cope with the rising salinity of Arctic ... today is best known for its tundra and polar bear ... 38 million years ago during what is known as the ... temperate forest with brackish water, home to a variety of ... giant tortoises. Much of what is known about the region ...
(Date:7/9/2014)... be on the verge of an economy driven by methane, ... coal and is undergoing a production boom. It has poised ... research is casting serious doubts over just how climate-friendly it ... News (C&EN), the weekly news magazine of the American ... correspondent at C&EN, explains that when burned as a fuel ...
(Date:7/9/2014)... Cholinergic inhibitors and N-methyl-D-aspartate receptor antagonists can ... fail to affect irreversible cognitive dysfunction and ... brain. Amyloid beta peptide (Aβ) vaccines reduced ... disease (AD) transgenic mouse model, and significantly ... Cao and his team, First Affiliated Hospital ...
Breaking Biology News(10 mins):Shark teeth analysis provides detailed new look at Arctic climate change 2Shark teeth analysis provides detailed new look at Arctic climate change 3
... the frontal cortex in adults, researchers have shown that this ... actions. , It has been known for over 100 ... left frontal cortex, he or she often suffers difficulties in ... impairments, it has been difficult for researchers to test the ...
... high levels of antibodies against the Epstein-Barr virus, the ... likely to develop multiple sclerosis 15 to 20 years ... will appear in the June 2006 print issue of ... Researchers have long suspected that external factors may influence ...
... The cholesterol-lowering medications called statins do not appear to ... to a meta-analysis of previous studies in the January ... that statins reduce the risk of developing cancer, the ... "Statins have been studied in numerous large-scale, randomized, ...
Cached Biology News:Big hips, big belly? It's in your genes, Joslin-led study shows 2Statins have neutral effect on risk of cancer 2
... The IHC Select Immunophosphatase Secondary Detection System ... IHC Select Prediluted Primary Antibody reagents, which ... qualitative identification of antigens by light microscopy ... Secondary Detection System may also be used ...
... FLISP Assay with SR-101 Labeled Substrates ... • Accurately measure serine protease activation ... • B-Bridge's FLISP Kits utilize cell-permeable, ... (FLISPs) to measure chymotrypsin-like activity in ...
From the company that first brought you the chromatin immunoprecipitation (ChIP) kit, a new and improved kit, EZ-ChIP, is now available to make your experiments easier, quicker, and most importantly,...
The PDS-1000 He Hepta system includes the PDS-1000 He biolistic system and the Hepta adaptor....
Biology Products: